April 3, 2025
Pembrolizumab plus concurrent chemoradiotherapy shows ongoing antitumor activity after about 5 years of follow-up in patients with unresectable, locally advanced, stage III non–small cell lung cancer […]
April 3, 2025
Durvalumab consolidation therapy reduced the rate of extrathoracic metastases vs placebo and prolonged the time to progression or death due to any metastases in patients with […]
April 2, 2025
TOPLINE: Compared with chemotherapy, immune checkpoint inhibitors (ICIs) were associated with improved overall survival in patients with microsatellite instable metastatic colorectal cancer (CRC), particularly when used […]
April 1, 2025
TOPLINE: Low-dose CT screening in a high-risk population detected lung cancer in 2.0% of participants, with nearly 80% of cases diagnosed at stage I or II. […]
April 1, 2025
Renier Brentjens, MD, PhD Renier Brentjens, MD, PhD, one of the pioneers in the development of chimeric antigen receptor (CAR) T-cell therapy, is poised to see […]
April 1, 2025
BOSTON — Key DNA and chromosomal and immune cell changes in early-stage lung adenocarcinoma show significant associations with outcomes, representing potentially important early predictors to guide […]
April 1, 2025
An enhanced prophylactic regimen using widely available and easy-to-use agents significantly reduced the incidence and severity of dermatologic reactions associated with first-line amivantamab plus lazertinib in […]
April 1, 2025
Back in 2014, a woman with advanced cancer pushed Adrienne Boire’s scientific life in a whole new direction. The cancer, which had begun in the breast, […]
April 1, 2025
The US Food and Drug Administration (FDA) has approved a perioperative durvalumab (Imfinzi, AstraZeneca) regimen for adults with muscle-invasive bladder cancer. Specifically, the indication is for […]